Market Announcement 4 August 2025 Attached for the information of the market are ASX's query letters to Alterity Therapeutics Limited (ASX:ATH) dated 24 July 2025 and 30 July 2025 and ATH's responses 28 July 2025 and 3 A

Attached for the information of the

market are ASX's query letters to Alterity Therapeutics Limited (ASX:ATH) dated 24 July 2025 and 30 July 2025 and ATH's responses

28 July 2025 and 3 August 2025.

Reference: ODIN111104

Alterity Therapeutics Limited

Suite 4, Level 14, 350 Collins Street

By email: amacnish@alteritytx.com

Alterity Therapeutics Limited ( ATH'): ASX

ASX refers to the following:

"an entity becomes aware

of information if, and as soon as, an officer of the entity (or, in the case of a trust, an officer of the responsible entity) has, or

ought reasonably to have, come into possession of the information in the course of the performance of their duties as an officer of that

"MAP should only be used

to publish information that is appropriately given to ASX under the Listing Rules or the Corporations Act for publication to the market.

It should not be used as a guise to publish material that is really promotional, political or tendentious in nature."

"Whether information

has the quality of being confidential is a question of fact, not one of the intention or desire of the entity. Accordingly, even though

an entity may consider information to be confidential and its disclosure to be a breach of confidence, if it is in fact disclosed by those

who know it, then it is no longer a secret and it ceases to be confidential information for the purposes of this rule."

Request for information

Having regard to the above, ASX asks ATH to respond separately

to each of the following questions:

Please answer separately for each of the items in question

1 above and provide details of the prior announcement if applicable.

When and where to send your response

This request is made under Listing

Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than 9:30 AM AEST Wednesday,

You should note that if the information

requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions

mentioned in Listing Rule 3.1A, ATH's obligation is to disclose the information immediately'. This may require the

information to be disclosed before the deadline set out above and may require ATH to request a trading halt immediately if trading in

ATH's securities is not already halted or suspended.

should be sent by e-mail to ListingsComplianceMelbourne@asx.com.au. It should not be sent directly to the ASX Market Announcements

Office. This is to allow us to review your response to confirm that it is in a form appropriate for release to the market, before it is

published on the ASX Market Announcements Platform.

If you are unable to respond to this letter by the time specified

above, ASX will likely suspend trading in ATH's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you

should have regard to ATH's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 Continuous Disclosure: Listing

Rules 3.1 - 3.1B. It should be noted that ATH's obligation to disclose information under Listing Rule 3.1 is not confined

to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

We reserve the right to release all or any

part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A. The usual course

is for the correspondence to be released to the market.

Reference: ODIN111263

Alterity Therapeutics Limited

Suite 4, Level 14, 350 Collins Street

By email: amacnish@alteritytx.com

Alterity Therapeutics Limited( ATH'): Further

ASX refers to the following:

The Company made an isolated

error in designating the Announcement' market sensitive. Despite this error being a one-off occurrence, the Company is promptly

taking action to review all internal governance processes. See also response to question 2 (b) below."

Given that the publication

presented similar data to what had previously been disclosed to the market, we did not consider that a reasonable person would expect

this release to have a material effect on the price or value of our securities. Moreover, while the presentations and publications described

novel methods to diagnose and track Multiple System Atrophy but did not include any data regarding a therapy being developed by the Company."

The Company is promptly actioning

a review of all internal governance processes to ensure this miscommunication does not happen again."

"as at the date of this notice there is no

information to be disclosed which is excluded information' (as defined in sections 708A(7) and 708A(8) of the Corporations

Act) which is required to be disclosed by the Company."

"ASX is alive to listed entities making market

announcements with a view to "ramping up" the price of their securities. Ramping announcements come in many forms, including:

Footnote 294 states: "These types of updates are

more appropriately given in a quarterly activities report under Listing Rule 4.7C rather than in a stand-alone announcement."

detects what it suspects to be a ramping announcement, it will give careful consideration to suspending the entity's

securities from trading and issuing a query letter to the entity asking the entity:

"an entity becomes aware

of information if, and as soon as, an officer of the entity (or, in the case of a trust, an officer of the responsible entity) has, or

ought reasonably to have, come into possession of the information in the course of the performance of their duties as an officer of that

"Whether information

has the quality of being confidential is a question of fact, not one of the intention or desire of the entity. Accordingly, even though

an entity may consider information to be confidential and its disclosure to be a breach of confidence, if it is in fact disclosed by those

who know it, then it is no longer a secret and it ceases to be confidential information for the purposes of this rule."

release information that is for release to the market to any +person until it has given the information to ASX and has received

an acknowledgement that ASX has released the information to the market."

delay between ATH becoming aware of the publication on 15 July 2025 and the release of the Announcement on MAP on 24 July 2025, to accept

ATH's position that the relevant information was not information required for release under the Listing Rules, it would appear to

ASX that ATH engaged in ramping conduct.

Request for Information

Having regard to the above, ASX asks

ATH to respond separately to each of the following questions:

When and where to send your response

This request is made under Listing Rule 18.7. Your

response is required as soon as reasonably possible and, in any event, by no later than 9:30 AM AEST Monday, 4 August 2025.

You should note that if the information

requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the

exceptions mentioned in Listing Rule 3.1A, ATH's obligation is to disclose the information immediately'. This may

require the information to be disclosed before the deadline set out above and may require ATH to request a trading halt immediately

if trading in ATH's securities is not already halted or suspended.

Your response should be sent by